2022 World Conference on Lung Cancer (ePosters)-EP08.02-151. A Real World Evidence of Lorlatinib for Taiwanese with advanced ALK Positive Non-Small Cell Lung Cancer

EP08.02-151. A Real World Evidence of Lorlatinib for Taiwanese with advanced ALK Positive Non-Small Cell Lung Cancer

Pdf Summary

A real-world study conducted in Taiwan suggests that lorlatinib, a third-generation tyrosine kinase inhibitor (TKI), is an effective and safe therapy for patients with advanced ALK-positive non-small cell lung cancer (NSCLC). The study aimed to evaluate the treatment patterns, clinical outcomes, therapeutic effects, and safety profile of lorlatinib in a real-world clinical setting.<br /><br />The study included 52 patients with ALK rearrangement who received lorlatinib treatment. The median age of the patients was 52.3 years, and 76.9% of them were non-smokers. The majority of patients (78.8%) had brain metastasis at the start of lorlatinib treatment. Lorlatinib was prescribed as the second TKI in 10 patients, the third TKI in 25 patients, and the fourth or later TKI in 17 patients.<br /><br />The study found that the overall response rate (ORR) was 21.2% and the disease control rate (DCR) was 84.5%. The intra-cranial disease objective response rate was 28.8%. The median progression-free survival (PFS) was 18.4 months, with a median PFS of 14.6 months for lorlatinib as the third TKI and 9.5 months for lorlatinib as the fourth or later TKI. The one-year overall survival rate was 79.0%.<br /><br />The most common adverse events reported were hyperlipidemia (65.4%), body weight gain (13.5%), and edema (7.7%). Grade 3/4 hyperlipidemia was reported in four patients, and grade 3/4 hyperglycemia was reported in two patients.<br /><br />Overall, the study suggests that lorlatinib is an effective and well-tolerated therapy for Taiwanese patients with advanced ALK-positive NSCLC. The treatment outcomes and safety profile were consistent with those reported in global clinical trials. These findings contribute to the real-world evidence supporting the use of lorlatinib in clinical practice.

Asset Subtitle

Wade Fang

Meta Tag

Speaker Wade Fang

Topic Metastatic Non-small Cell Lung Cancer - Molecular Targeted Treatments

Keywords

lorlatinib

tyrosine kinase inhibitor

ALK-positive non-small cell lung cancer

real-world study

treatment patterns

clinical outcomes

therapeutic effects

safety profile

response rate

progression-free survival